ATE546148T1 - Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung - Google Patents
Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlungInfo
- Publication number
- ATE546148T1 ATE546148T1 AT06761149T AT06761149T ATE546148T1 AT E546148 T1 ATE546148 T1 AT E546148T1 AT 06761149 T AT06761149 T AT 06761149T AT 06761149 T AT06761149 T AT 06761149T AT E546148 T1 ATE546148 T1 AT E546148T1
- Authority
- AT
- Austria
- Prior art keywords
- combination
- fluoropyrimidines
- cancer treatment
- chlorite solutions
- fluoropyrimidine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 229910001919 chlorite Inorganic materials 0.000 title abstract 3
- 229910052619 chlorite group Inorganic materials 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 title 1
- 150000005699 fluoropyrimidines Chemical class 0.000 title 1
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 abstract 2
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 abstract 1
- UEJQGOKMPMUMTO-UHFFFAOYSA-N C(C#C)OC1=NC=C(C(=N1)OCC#C)F Chemical compound C(C#C)OC1=NC=C(C(=N1)OCC#C)F UEJQGOKMPMUMTO-UHFFFAOYSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 abstract 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 229960004117 capecitabine Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 abstract 1
- 229950005454 doxifluridine Drugs 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70107505P | 2005-07-21 | 2005-07-21 | |
| PCT/CA2006/001187 WO2007009245A1 (en) | 2005-07-21 | 2006-07-21 | Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE546148T1 true ATE546148T1 (de) | 2012-03-15 |
Family
ID=37668401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06761149T ATE546148T1 (de) | 2005-07-21 | 2006-07-21 | Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20080292729A1 (de) |
| EP (2) | EP1906977B1 (de) |
| JP (2) | JP2009501734A (de) |
| AT (1) | ATE546148T1 (de) |
| AU (1) | AU2006272343B2 (de) |
| CA (1) | CA2616008A1 (de) |
| ES (1) | ES2384267T3 (de) |
| WO (1) | WO2007009245A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
| WO2007033180A1 (en) | 2005-09-12 | 2007-03-22 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds |
| AU2006291134C1 (en) | 2005-09-12 | 2013-08-15 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same |
| US9855212B2 (en) | 2009-10-30 | 2018-01-02 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases |
| CA2807723A1 (en) * | 2010-08-13 | 2012-02-16 | Servet Buyuktimkin | Foamable compositions of stabilized chlorite |
| RU2014130080A (ru) | 2011-12-22 | 2016-02-10 | Нуво Рисерч Гмбх | Липосомальные композиции хлоритов или хлоратов |
| WO2014037927A1 (en) | 2012-09-10 | 2014-03-13 | Nuvo Research Gmbh | Chlorate compositions and use of chlorate for treating radiation exposure |
| CN106619689B (zh) * | 2016-12-30 | 2018-05-01 | 陈晓华 | 一种用于治疗癌症的药物组合物、试剂盒及其应用 |
| BR112023000427A2 (pt) | 2020-07-07 | 2023-03-28 | Wiab Water Innovation Ab | Composições e métodos para desinfectar, tratar e prevenir infecções microbianas |
| WO2023021329A1 (en) | 2021-08-17 | 2023-02-23 | Wiab Water Innovation Ab | Compositions and methods to disinfect, treat and prevent microbial infections |
| US12611425B2 (en) | 2022-10-10 | 2026-04-28 | Wiab Water Innovation Ab | Compositions and methods for treatment and prevention of pathogens |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3515748A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Verwendung einer isotonen chloritmatrix-loesung bei der behandlung von tumoren |
| CA1327358C (en) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| US6258360B1 (en) * | 1989-05-04 | 2001-07-10 | Igen International, Inc. | Prodrugs activated by targeted catalytic proteins |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| IL148189A0 (en) * | 1999-08-18 | 2002-09-12 | Oxo Chemie Ag | Chemically-stabilized chlorite solutions for treating cancer and other diseases |
| DE602004010900D1 (de) * | 2003-05-08 | 2008-02-07 | Eisai R&D Man Co Ltd | Medizinische zusammensetzungen enthaltend n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzensulfonamid und weitere cytostatika |
| RS20150135A1 (sr) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| KR20060054412A (ko) * | 2003-08-01 | 2006-05-22 | 와이어쓰 홀딩스 코포레이션 | 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도 |
| JP2007511499A (ja) * | 2003-11-13 | 2007-05-10 | ファーマ・マール・エス・アー・ウー | コンビネーション |
-
2006
- 2006-07-21 AT AT06761149T patent/ATE546148T1/de active
- 2006-07-21 EP EP06761149A patent/EP1906977B1/de not_active Expired - Lifetime
- 2006-07-21 US US11/996,488 patent/US20080292729A1/en not_active Abandoned
- 2006-07-21 AU AU2006272343A patent/AU2006272343B2/en not_active Ceased
- 2006-07-21 EP EP11179750A patent/EP2428213A1/de not_active Withdrawn
- 2006-07-21 CA CA002616008A patent/CA2616008A1/en not_active Abandoned
- 2006-07-21 ES ES06761149T patent/ES2384267T3/es not_active Expired - Lifetime
- 2006-07-21 JP JP2008521763A patent/JP2009501734A/ja active Pending
- 2006-07-21 WO PCT/CA2006/001187 patent/WO2007009245A1/en not_active Ceased
-
2013
- 2013-01-24 US US13/748,931 patent/US20130202719A1/en not_active Abandoned
- 2013-03-13 JP JP2013050962A patent/JP2013173745A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1906977B1 (de) | 2012-02-22 |
| JP2013173745A (ja) | 2013-09-05 |
| EP1906977A1 (de) | 2008-04-09 |
| WO2007009245A1 (en) | 2007-01-25 |
| EP1906977A4 (de) | 2008-09-03 |
| US20080292729A1 (en) | 2008-11-27 |
| US20130202719A1 (en) | 2013-08-08 |
| AU2006272343B2 (en) | 2012-09-13 |
| EP2428213A1 (de) | 2012-03-14 |
| JP2009501734A (ja) | 2009-01-22 |
| CA2616008A1 (en) | 2007-01-25 |
| AU2006272343A1 (en) | 2007-01-25 |
| ES2384267T3 (es) | 2012-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1906977A4 (de) | Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung | |
| EP4684786A3 (de) | Pyridopyrimidinderivate als kras-g12c- und kras-g12d-hemmer bei der behandlung von krebs | |
| IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
| GEP20237560B (en) | Fused pyrazine derivatives as a2a / a2b inhibitors | |
| MX2019005834A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2. | |
| DK1450799T5 (da) | Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| ATE521608T1 (de) | Glucokinaseaktivatoren | |
| ZA200700057B (en) | 2, 4, 6-Trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | |
| DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| UA100540C2 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| MX2018011975A (es) | Terapia de combinacion para tratamiento de leucemia mieloide aguda. | |
| MY199382A (en) | Methods of treating circadian rhythm sleep disorders | |
| EP3895725A3 (de) | Verfahren zur tumorbehandlung mit rekombinantem interferon mit veränderter räumlicher konfiguration | |
| NO20074360L (no) | Behandling av metastaterte tumorer | |
| MX2025004864A (es) | Compuestos que median la degradacion de proteinas y metodos de uso de los mismos | |
| IL276235B2 (en) | Use of Minfrain to reduce tumor growth | |
| MX2023006434A (es) | Inhibidores de quinasa y usos de los mismos. | |
| WO2016201365A3 (en) | Methods for treating cancers | |
| GB0916188D0 (en) | Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders | |
| MXPA05002477A (es) | Asialo-interferones y el tratamiento de cancer de higado. |